Zydena is under phase 2 clinical studies for portal hypertension

Dong-A PharmTech Co., affiliate of Dong-A Pharmaceutical. Co., announced on February 25 that it has initiated a 200 patient, phase 2 clinical study in Europe to investigate the use of Zydena (udenafil), a long-acting phosphodiesterase type 5 inhibitor, for portal hypertension.

Zydean is emerging as a potential new medicine in the growing and underserved portal hypertension market which is pr...